Abstract
Abstract
Background
Similarities in the hijacking mechanisms used by SARS-CoV-2 and several types of cancer, suggest the repurposing of cancer drugs to treat Covid-19. CK2 kinase antagonists have been proposed for cancer treatment. A recent study in cells infected with SARS-CoV-2 found a significant CK2 kinase activity, and the use of a CK2 inhibitor showed antiviral responses. CIGB-300, originally designed as an anticancer peptide, is an antagonist of CK2 kinase activity that binds to the CK2 phospho-acceptor sites. Recent preliminary results show the antiviral activity of CIGB-300 using a surrogate model of coronavirus. Here we present a computational biology study that provides evidence, at the molecular level, of how CIGB-300 may interfere with the SARS-CoV-2 life cycle within infected human cells.
Methods
Sequence analyses and data from phosphorylation studies were combined to predict infection-induced molecular mechanisms that can be interfered by CIGB-300. Next, we integrated data from multi-omics studies and data focusing on the antagonistic effect on the CK2 kinase activity of CIGB-300. A combination of network and functional enrichment analyses was used.
Results
Firstly, from the SARS-CoV studies, we inferred the potential incidence of CIGB-300 in SARS-CoV-2 interference on the immune response. Afterwards, from the analysis of multiple omics data, we proposed the action of CIGB-300 from the early stages of viral infections perturbing the virus hijacking of RNA splicing machinery. We also predicted the interference of CIGB-300 in virus-host interactions that are responsible for the high infectivity and the particular immune response to SARS-CoV-2 infection. Furthermore, we provided evidence of how CIGB-300 may participate in the attenuation of phenotypes related to muscle, bleeding, coagulation and respiratory disorders.
Conclusions
Our computational analysis proposes putative molecular mechanisms that support the antiviral activity of CIGB-300.
Funder
Center for Genetic Engineering and Biotechnology
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine
Reference92 articles.
1. Recknor CP. Evaluating safety, pharmacokinetics and clinical benefit of silmitasertib (CX-4945) in subjects with moderate COVID-19. https://www.clinicaltrialsgov/ct2/show/record/NCT04663737. 2020.
2. Abe M, Lin J, Nagata K, Okuwaki M. Selective regulation of type II interferon-inducible genes by NPM1/nucleophosmin. FEBS Lett. 2018;592(2):244–55.
3. Akbar MR, Pranata R, Wibowo A, Lim MA, Sihite TA, Martha JW. The prognostic value of elevated creatine kinase to predict poor outcome in patients with COVID-19—a systematic review and meta-analysis. Diabetes Metab Syndr. 2021;15(2):529–34.
4. Batista-Albuerne N, González-Méndez L, García-García I, et al. Phase I study of CIGB-300 administered intravenously in patients with relapsed/refractory solid tumors. J Med Oncol. 2018;1(1):4.
5. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献